Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Paz Ares, Luis G ^a   Altug, Sedat ^b   Vaury, Alexandra T ^b   Jaime, Jesús C ^a   Russo, Francesca ^c   Visseren Grul, Carla ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c Eli Lilly and Co   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PEMETREXED; PLACEBO; SODIUM CHLORIDE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HUMAN TISSUE; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; THERAPY EFFECT; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; METHODOLOGY; PALLIATIVE THERAPY; PATHOLOGY; REMISSION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PALLIATIVE CARE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RESEARCH DESIGN; YOUNG ADULT;

EID: 77950357310     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-85     Document Type: Article

References (43)

1. Swisher SG. Surgical treatment of locally advanced non-small cell lung cancer. Lung Cancer 2002, 118-141. New York: Springer, Fossella FV, Komaki R, Putnam JB Jr, [Buzdar AU, Freedman RS (Series Editors): M. D. Anderson Cancer Care Series.].
2. D'Addario G, Felip E, . ESMO Guidelines Working Group Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):iv68-iv70. ESMO Guidelines Working Group.
3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR, . American Society of Clinical Oncology American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353. 10.1200/JCO.2004.09.053, 14691125, American Society of Clinical Oncology.
4. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005, 10(Suppl 3):1-10. 10.1634/theoncologist.10-90003-1, 16368866.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, . Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98. 10.1056/NEJMoa011954, 11784875, Eastern Cooperative Oncology Group.
6. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M, . Italian Lung Cancer Project Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002, 20:4285-4291. 10.1200/JCO.2002.02.068, 12409326, Italian Lung Cancer Project.
7. Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 2007, 8:38-46. 10.1007/s11864-007-0020-6, 17634834.
8. Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25:5233-5239. 10.1200/JCO.2007.10.8134, 18024869.
9. Socinski MA, Stinchcombe TE. Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol 2007, 25:5155-5157. 10.1200/JCO.2007.13.4015, 18024862.
10. Soon YY, Askie L, Stockler M, Boyer M. Optimal duration of chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis [abstract]. J Thorac Oncol 2007, 2(8 Suppl 4). PD4-2-1.
11. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005, 23:3235-3242. 10.1200/JCO.2005.08.409, 15886311.
12. Mok TS, Zhou C, Kim S, Wu Y, Perng R, . on behalf of the E/SE Asian TRUST investigators Efficacy and safety of erlotinib in >1200 East/South-East (E/SE) Asian patients (pts) with advanced non-small-cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2008, 26(Suppl):19001. on behalf of the E/SE Asian TRUST investigators.
13. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
14. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234. 10.1200/JCO.2007.14.5466, 19188680.
15. Lynch TJ, Brahmer J, Fischbach N, Garst J, Kumar P, Spigel DR, Teng S, Vidaver R, Wang L, Navarro W, . for the ARIES Investigators Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) [abstract]. J Clin Oncol 2008, 26(Suppl):8077. for the ARIES Investigators.
16. Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K, Gatzemeier U, Bajeta E, Emig M, Pereira JR. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2008, 26(Suppl):3.
17. Gridelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments. Oncologist 2007, 12:1183-1193. 10.1634/theoncologist.12-10-1183, 17962612.
18. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551. 10.1200/JCO.2007.15.0375, 18506025.
19. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 2009, 14:253-263. 10.1634/theoncologist.2008-0232, 19221167.
20. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM. LY23 a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1514, 57:1116-1123.
21. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999, 26(2 Suppl 6):42-47.
22. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo Iacono M, Cappia S, Papotti M, Scagliotti GV. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596. 10.1002/cncr.22208, 16955506.
23. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008, 3:1112-1118. 10.1097/JTO.0b013e3181874936, 2639211, 18827606.
24. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999, 26(2 Suppl 6):68-73.
25. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003, 22:7431-7457. 10.1038/sj.onc.1206946, 14576850.
26. Rinaldi M, Belvedere O, Cauchi C, Defferrari C, Viola G, Grossi F. Maintenance chemotherapy in non-small cell lung cancer. Ann Oncol 2006, 17(Suppl 2):ii67-ii70. 10.1093/annonc/mdj928, 16608989.
27. Grossi F, Aita M, Follador A, Defferrari C, Brianti A, Sinaccio G, Belvedere O. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007, 12:451-464. 10.1634/theoncologist.12-4-451, 17470688.
28. Gridelli C, Maione P, Rossi A, Ferrara ML, Bareschino MA, Schettino C, Sacco PC, Ciardiello F. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?. Oncologist 2009, 14:137-147. 10.1634/theoncologist.2008-0152, 19190239.
29. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M, . Central European Cooperative Oncology Group CECOG Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163. 10.1016/j.lungcan.2006.01.006, 16569462, Central European Cooperative Oncology Group CECOG.
30. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598. 10.1200/JCO.2008.17.1405, 19075278.
31. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597. 10.1200/JCO.2004.08.163, 15117980.
32. Ciuleanu TE, Brodowicz T, Belani CP, Kim J, Krzakowski M, Laack E, Wu Y, Peterson P, Adachi S, Zielinski CC. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study [abstract]. J Clin Oncol 2008, 26(Suppl):8011.
33. Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, Wu YL, Peterson P, Krejcy K, Zielinski C. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2009, 27(Suppl):CRA8000.
34. Zielinski CC, Yang S, Santoro A, Ramlau R, Liepa AM, Peterson P, Brodowicz T, Madhavan J, Franke FA, Cucevic B. Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: evidence from a large randomized study [abstract]. J Clin Oncol 2008, 26(Suppl):8060.
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
36. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990, 16:199-208. 10.1016/0168-8510(90)90421-9, 10109801.
37. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). , http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_v30
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
39. Cox DR, Snell EJ. Analysis of Binary Data 1989, London: Chapman & Hall, 2.
40. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003, 21:2933-2939. 10.1200/JCO.2003.02.563, 12885812.
41. Belani CP, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ. Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small cell lung cancer (NSCLC) patients [abstract]. J Clin Oncol 2005, 23(16 Suppl):7143.
42. Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006, 1:25-30. 10.1097/01243894-200601000-00007, 17409823.
43. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644. 10.1200/JCO.2003.11.136, 12860938.